GW Pharmaceuticals plc (GWPH) Analysts See $-2.39 EPS

Analysts expect GW Pharmaceuticals plc (NASDAQ:GWPH) to report $-2.39 EPS on December, 3.They anticipate $0.21 EPS change or 9.63 % from last quarter’s $-2.18 EPS. After having $-1.26 EPS previously, GW Pharmaceuticals plc’s analysts see 89.68 % EPS growth. The stock increased 0.71% or $0.87 during the last trading session, reaching $123.02. About 389,350 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 29.17% since December 2, 2017 and is uptrending. It has outperformed by 13.55% the S&P500.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

Among 6 analysts covering GW Pharma (NASDAQ:GWPH), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GW Pharma has $23500 highest and $181 lowest target. $202.67’s average target is 64.75% above currents $123.02 stock price. GW Pharma had 7 analyst reports since June 25, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Buy” rating and $23500 target in Monday, June 25 report. The rating was maintained by Morgan Stanley with “Overweight” on Thursday, October 11. The rating was maintained by Morgan Stanley with “Overweight” on Friday, September 7. The rating was maintained by Bank of America with “Buy” on Tuesday, June 26. Goldman Sachs initiated GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Tuesday, June 26. Goldman Sachs has “Buy” rating and $18800 target.

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company has market cap of $3.98 billion. It operates through three divisions: Commercial, Sativex Research and Development, and Pipeline Research and Development. It currently has negative earnings. The firm markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.

More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Finance.Yahoo.com which released: “3 Smokin’ Hot Marijuana Stocks to Trade for the Next High – Yahoo Finance” on November 06, 2018, also Nasdaq.com with their article: “GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards? – Nasdaq” published on August 06, 2018, Seekingalpha.com published: “Morgan Stanley upgrades Teva and Bausch in premarket analyst action – Seeking Alpha” on November 05, 2018. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Nasdaq.com and their article: “European ADRs Move Higher in Monday Trading – Nasdaq” published on November 26, 2018 as well as Benzinga.com‘s news article titled: “Earnings Scheduled For November 27, 2018 – Benzinga” with publication date: November 27, 2018.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.